In his presentation at Ending Age-Related Diseases 2020, LEAF board member Javier Noris discussed the Longevity Impact Fund, the reasons why biotechnology funding has been lacking, the “valley of death” that must be crossed in order to fully fund early-stage research through the clinical trial process, and new ways in which venture capital can fund high-risk biotechnology ventures.
HELP SPREAD THE WORD
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
Scientists have managed to extend the lifespan of C. elegans nematode worms by as much as 135% by blocking an insulin-related pathway very late in life [1]. The long-lived mutants Back in […]
A commercially available alpha-ketoglutarate-based supplement has been shown to roll back biological age by 7 years on average in a retrospective human study [1]. Live slower, die […]
On this episode of Lifespan News, Brent Nally talks about how Gitcoin Grants Round 12 has kicked off with over $2 million dollars committed in matching funds for projects. Script Gitcoin Grants […]
Researchers publishing in GeroScience have found that carotid artery stenosis, a consequence of hypertension, is linked to a lack of blood flow in the eyes. A disease that restricts blood flow to the brain Carotid artery stenosis (CAS) […]
Dr. Matt Kaeberlein and colleagues recently published a review summarizing anti-aging diets as well as their misconceptions [1]. Caloric restriction, fasting-mimicking diets, and intermittent fasting While fasting […]
You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.
Write a comment: